Eczema and X-linked agammaglobulinaemia

Area of Science:

• Immunology
• Genetics
• Dermatology

Background:

• X-linked agammaglobulinaemia (XLA) is a primary immunodeficiency characterized by defective B lymphocyte development due to Bruton's tyrosine kinase mutations.
• Typically presents in infancy with recurrent bacterial sinopulmonary infections, low immunoglobulin levels (IgG, IgM, IgA), and affects only males.
• Cutaneous manifestations commonly include pyogenic infections, but eczema is also observed with increased frequency.

Observation:

• An 8-year-old boy with XLA presented with eczematous skin lesions, recurrent otitis media, and pyrexias.
• Treatment with intravenous immunoglobulin (IVIg) replacement therapy was initiated for his diagnosed XLA.
• The patient subsequently experienced eczematous exacerbations several days after IVIg administration.

Findings:

• The case demonstrates a potential association between IVIg therapy and worsening eczema in a patient with XLA.
• This presentation expands the known spectrum of cutaneous manifestations in XLA, particularly in response to treatment.

Implications:

• Highlights the importance of considering dermatological monitoring during immunoglobulin replacement therapy in XLA patients.
• Suggests a need for further investigation into the immunological mechanisms underlying IVIg-induced eczematous reactions in primary immunodeficiencies.
• Informs clinical management strategies for managing skin conditions in boys diagnosed with XLA.